Introduction {#Sec1}
============

In the female reproductive system, epithelial ovarian cancer (EOC) is the third most common cancer and the first leading cause of cancer deaths \[[@CR1]\]. Main reasons for the high mortality include late diagnosis and drug resistance \[[@CR2]\]. Currently, the standard treatment is platinum-based chemotherapy following primary debulking surgery for advanced patients. However, approximately 20% of patients fail to respond to platinum-based chemotherapy \[[@CR3]\], and up to 75% of patients among the initial responders eventually relapse within less than 2 years \[[@CR4]\]. Accordingly, primary or acquired resistance to chemotherapeutic drugs is a major obstacle in the treatment of ovarian cancer and the main contributing factor for the cancerous death.

Increasing evidence also has shown that epigenetic changes may play an important role in chemotherapy resistance of ovarian cancer \[[@CR5]\]. In particular, it has been suggested that DNA methylation, a well-studied epigenetic change, may serve as a potential biomarker for chemotherapy-resistant phenotypic screening \[[@CR6]\]. Nevertheless, the more detailed mechanism of how DNA methylation affects the drug-resistant still needs to be explored. We used reduced representation bisulfite sequencing (RRBS) screened out a significantly hypermethylated upstream region of *hMSH2*, which involved in DNA mismatch repair (MMR) system. In mammals, MMR genes play a key role in not only DNA replication and repair \[[@CR7]\] but also DNA damage signals and consequent apoptosis \[[@CR8]\]. Because chemotherapy is a mainstay of DNA-damaging agents in numerous cancer therapies, loss of MMR proteins renders cells resistant to DNA-damaging regents \[[@CR9], [@CR10]\]. Interestingly, the existing studies about *hMSH2* showed inconsistent opinions on whether loss of hMSH2 expression can lead to resistance of cisplatin or not. Early studies using immunohistochemical staining with tumor sections suggested hMSH2 expression was not highly predictive of drug sensitivity as measured by response, progression-free survival (PFS), or overall survival (OS) \[[@CR11], [@CR12]\]. However, a recent study using whole-genome CRISPR (clustered regularly interspaced short palindromic repeats) screen in a bladder cancer cell line identified that *hMSH2* was the most significantly enriched gene that promotes resistance to cisplatin \[[@CR13]\]. In addition to genetic mutations, promoter hypermethylation is an important mechanism for the loss of *hMSH2* expression and has been reported to be associated with some human cancers \[[@CR14], [@CR15]\]. In ovarian cancer, the methylation frequency of *hMSH2* promoter has been reported to be as high as 51.7%, and the methylation of *hMSH2* correlated with histological grade and lymphatic metastasis \[[@CR16]\]. However, to date, there are no reports about the role of *hMSH2* expression loss caused by aberrant methylation of the promoter region in platinum resistance.

This study is to investigate the role of aberrant methylation of *hMSH2* upstream region involved in platinum resistance in EOC. Firstly, we have examined the possible role of higher expression of hMSH2 induced by global de-methylation and decreased expression by *hMSH2* knockdown on ovarian cancer cells to cisplatin. Further, we also examined the effects of methylation status and expression of hMSH2 in ovarian tumor samples on prognosis of EOC patients.

Results {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

Archived information of 150 EOC patients was obtained from the Hebei Medical University, Fourth Hospital. All patients received platinum-based chemotherapy following primary debulking surgery and followed up for 3 years at least. The median age of patients was 56 years old (age ranges from 20 to 78). In terms of histology, 85 (56.7%) out of the 150 patients were diagnosed with serous adenocarcinoma, 41 (27.3%) with endometrioid carcinoma, 9 (6.0%) with mucinous carcinoma, 6 (4.0%) with clear cell carcinoma, and 9 (6.0%) with mixed type. According to FIGO (International Federation of Gynecology and Obstetrics) staging, 112 cases (81.3%) had stage III--IV ovarian cancer and 28 cases (18.7%) in stages I--II. Histologically, 38 (25.3%) tumors were G1 grade, 67 (44.7%) were G2 grade, and 45 (30.0%) were G3 grade. Detailed information was shown in Table [1](#Tab1){ref-type="table"}. Table 1Patient information and dosimetric parametersCharactersHistology/stagePatients (*n*)MedianPercentage/rangeAge56 years20--78 yearsHistologySerous8556.7%Endometrioid4127.3%Mucinous96.0%Clear cell64.0%Mixed type96.0%FIGO stageI--II2818.7%III--IV12281.3%Histological gradeG13825.3%G26744.7%G34530.0%Tumor residual size0 cm4228.0%≤ 1 cm7147.3%\> 1 cm3724.7%Tumor size≤ 10 cm6744.7%\> 10 cm8355.3%Platinum-basedCisplatin-based3120.7%Carboplatin-based11979.3%Follow-up time15036.5 months2--86 months*FIGO* International Federation of Gynecology and Obstetrics

Screening with RRBS {#Sec4}
-------------------

Samples from 8 platinum-resistant and 8 platinum-sensitive EOC patients were screened using RRBS technique to identify differentially methylated loci between sets of samples. The detailed information of 16 patients was shown in Additional file [2](#MOESM2){ref-type="media"}: Table S1. In general, after removing the unqualified data, 276 valid hyper- or hypo-methylated regions were identified Additional file [3](#MOESM3){ref-type="media"}. We ranked these loci according to the *P* value of differential methylation regions (DMR) from lowest to highest and evaluated each site one by one to check whether there is any region that has a potential connection with the drug-resistant. Most loci on the top of the list were from transcript factors or regions with unknown function. Notably, among the non-transcript factor gene-related loci, an upstream region from − 1193 to − 1125 of the *hMSH2* gene was identified with a significant DMR *P* value of 1.06 × 10^−14^, meaning the methylation status of *hMSH2* was thought to be putatively related to EOC patients' response to platinum agents.

Global demethylation and expression changing of *hMSH2* in A2780 cells {#Sec5}
----------------------------------------------------------------------

Since in vitro evidence has shown that *hMSH2* was the most enriched gene for the cisplatin resistant \[[@CR13]\] and it also has been widely accepted that hypermethylation at promoter regions can suppress the gene expression; therefore, our hypothesis is that the hypermethylation of promoter for the *hMSH2* might account for the drug resistance. We first tested our hypothesis in A2780 cells, an ovarian cancer cell line that was established from tumor tissue from an untreated patient. The A2780 cells were treated with the 5-aza-dC, a global demethylation reagent, and the methylation of the *hMSH2* upstream region was assessed with MALDI-TOF mass spectrometry. The mass spectrometry results showed that the methylation level of the *hMSH2* upstream region was remarkably reduced by 1.9-fold by average after the administration of 15 μM 5-aza-dC for 72 h (*P* \< 0.05, Fig. [1](#Fig1){ref-type="fig"}a). Furthermore, RT-qPCR and western blot assays both demonstrated a significant increase of hMSH2 expression following treatment with 5-aza-dC 15 μM (*P* \< 0.05, Fig. [1](#Fig1){ref-type="fig"}b--d). More importantly, the hMSH2 expression level was positively correlated with the increasing concentrations of 5-aza-dC, which indicated a direct association of hMSH2 expression with the methylation. Fig. 1Effects of 5-aza-dC treatment on the ovarian cancer cellular sensitivity to cisplatin. **a** The alterations of the methylation level of *hMSH2* promoter in A2780 cells after 5-aza-dC treatment (15 μM) for 72 h. **b** The change of *hMSH2* mRNA expression after treated with the increasing concentrations of 5-aza-dC for 72 h. **c**, **d** Western bolt assay showed the increase trend of hMSH2 protein in A2780 cells after treated with the increasing concentrations of 5-aza-dC for 72 h. **e** CCK-8 assays suggested A2780 cells pre-treated with 5-aza-dC (15 μM) for 72 h showed the obvious decreased proliferation rates to cisplatin compared to control cells (DMSO treatment). **f** The cell apoptosis rates were significantly increased in A2780 pre-treated with 15 μM 5-aza-dC for 72 h than that in control cells (DMSO treatment) at several cisplatin concentrations by flow cytometry. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Each assay was performed in triplicate

Demethylation of *hMSH2* enhances sensitivity to cisplatin in A2780 cells {#Sec6}
-------------------------------------------------------------------------

Cell viability and apoptosis assays were performed to determine the effect of *hMSH2* demethylation in A2780 cells on cisplatin sensitivity. A2780 cells that had been pre-treated with 15 μM 5-aza-dC were exposed to 0, 5, 10, 15, 20, and 25 μM cisplatin, respectively, for 24 h. The control cells were pre-treated with DMSO. As shown in Fig. [1](#Fig1){ref-type="fig"}e, the cell viability rates of 5-aza-dC treatment groups showed obviously decreased compared with control groups. By flow cytometry, the cisplatin-induced apoptosis rates were remarkably increased in 5-aza-dC treatment groups compared with the control groups (*P* \< 0.05, Fig. [1](#Fig1){ref-type="fig"}f).

Suppression of hMSH2 increases cisplatin resistance in A2780 cells {#Sec7}
------------------------------------------------------------------

To further affirm that the expression level of hMSH2 can independently affect the sensitivity of cisplatin, we knocked down the expression of *hMSH2* in A2780 cells via shRNA. *hMSH2* mRNA and protein expression levels were reduced by 63% and 58% in the A2780 shRNA-hMSH2 group, respectively, compared with the A2780 shNC group (*P* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}a, b). Fig. 2The alteration of the sensitivity to cisplatin after a knockdown of *hMSH2* expression in A2780 cells. **a**, **b** RT-qPCR and western blot assay showed the reduced expression of hMSH2 in sh-hMSH2 cells compared to shNC cells. **c** CCK-8 assays showed a significant increase in the proliferation rates in the shRNA-hMSH2 cells compared with the shNC cells after cisplatin treatment at several concentrations for 24 h. **d** Flow cytometry showed that the apoptosis rate in the shRNA-hMSH2 cells was significantly lower than that in the shNC cells after exposure to cisplatin at the 20 μM concentration for 24 h. The A2780 cell apoptosis rates in each group. \**P* \< 0.05; \*\**P* \< 0.01. The experiments were repeated three times

Then, we compared the cisplatin sensitivity of *hMSH2* knockdown cells and control cells. CCK-8 assays showed a significant increase in the proliferation rates in the shRNA-hMSH2 group compared with the shNC group after cisplatin treatment at several concentrations for 24 h (*P* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}c). Next, flow cytometry further confirmed that the apoptosis rate in the shRNA-hMSH2 group was significantly lower than that in the shNC group after exposure to cisplatin at 20 μM concentration (*P* = 0.03, Fig. [2](#Fig2){ref-type="fig"}d).

Association between *hMSH2* promoter methylation level and platinum resistance of EOC patients {#Sec8}
----------------------------------------------------------------------------------------------

The previous cell studies suggested that hMSH2 expression can independently account for the cell susceptibility to cisplatin, and the expression level of hMSH2 was affected by the methylation. Therefore, we hypothesized that *hMSH2* promoter might be differentially methylated and thus accounts for varieties of drug sensibility in EOC patients. In the previous results, the RRBS assay has demonstrated that the upstream region from − 1193 to − 1125 of the *hMSH2* gene was significantly hypermethylated in the platinum-resistant group (Fig. [3](#Fig3){ref-type="fig"}a). To further confirm the findings of the RRBS assay, MALDI-TOF mass spectrometry was employed to examine the methylation level of this region in an independent group of samples that were from 18 platinum-resistant EOC patients and 22 platinum-sensitive EOC patients. The analysis from MALDI-TOF mass spectrometry revealed that the methylation level of the − 1164 CpG site was significantly higher in the platinum-resistant group than that in the platinum-sensitive group (*P* = 0.004, Fig. [3](#Fig3){ref-type="fig"}b). However, the methylation levels of the − 1191, − 1156, and − 1126 CpG sites were not significantly different between the two groups (all *P* \> 0.05) (Additional file [3](#MOESM3){ref-type="media"}). Fig. 3The methylation level of *hMSH2* promoter was associated with platinum-resistant in EOC patients. **a** Reduced representation bisulfite sequencing (RRBS) assay showed the region (− 1193 to − 1125 upstream) within the promoter of hMSH2 was hypermethylated in platinum-resistant patients compared with platinum-sensitive patients (*P* = 1.06 × 10^−14^). **b** The methylation of − 1164 CpG site was significantly hypermethylated in platinum-resistant patients compared with platinum-sensitive patients by MALDI-TOF mass. **c** The mRNA expression of *hMSH2* in platinum-resistant patients and platinum-sensitive patients. All experiments were repeated three times. **d** Images shown the expression of hMSH2 protein in EOC tumor tissues. \**P* \< 0.05; \*\**P* \< 0.01

Correlation analysis of *hMSH2* up-stream methylation status and its expression in EOC patients {#Sec9}
-----------------------------------------------------------------------------------------------

RT-qPCR was used to detect the mRNA levels of *hMSH2* in an extended sample group of 60 platinum-resistant EOC patients and 90 platinum-sensitive EOC patients. The *hMSH2* mRNA level in the platinum-resistant group was 1.95-fold lower than that in the platinum-sensitive group, and the difference was statistically significant (*P* = 0.004, Fig. [3](#Fig3){ref-type="fig"}c). Spearman's correlation analysis revealed that there was a significant negative connection between the methylation level of the *hMSH2* promoter and its mRNA expression (*P* = 0.02, *r* = −.41). The result demonstrated that the hypermethylation of *hMSH2* promoter may be responsible for the downregulation of its expression in EOC tumor tissues.

Further, among the 150 patient samples, IHC analysis was conducted to examine the protein expression of hMSH2 in 37 platinum-resistant EOC patients and 49 platinum-sensitive EOC patients. Compared with the platinum-sensitive group, the expression of the hMSH2 protein was significantly decreased in the platinum-resistant group (*P* = 0.03, Table [2](#Tab2){ref-type="table"}). Representative images of hMSH2 staining are shown in Fig. [3](#Fig3){ref-type="fig"}d. Table 2Associations of platinum-based chemotherapy resistance with hMSH2 protein expressionhMSH2 expressionResistant group, *n* (%)Sensitive group, *n* (%)*P*High21 (56.75)38 (77.55)0.03Low16 (43.24)11 (22.45)

High methylation of *hMSH2*promoter region correlates with poor EOC patients' prognosis {#Sec10}
---------------------------------------------------------------------------------------

Previously described methylation of *hMSH2* and its expression were divided into low and high groups based on their median value, respectively. Kaplan-Meier analysis demonstrated that patients in the *hMSH2* methylation^high^ group had shorter PFS and OS than those in *hMSH2* methylation^low^ group, and *hMSH2* expression^low^ group was associated with poorer prognosis compared to *hMSH2* expression^high^ group (Fig. [4](#Fig4){ref-type="fig"}a, b). Fig. 4The high methylation of *hMSH2* and its low mRNA expression are associated with poor survival in EOC patients. **a** Kaplan-Meier analysis of 150 EOC patients' survival according to the *hMSH2* expression. **b** Kaplan-Meier analysis of PFS and OS according to the *hMSH2* methylation level in 40 EOC patients

Based on the negative correlation between methylation status of *hMSH2* upstream region and its expression in EOC patients in this study, *hMSH2* expression index was included in multivariable analysis for survival. The results showed the *hMSH2* mRNA levels were significantly associated with OS when age, stage, grade, tumor size, and tumor residual size were included in the model (*P* = 0.03, HR = 1.91, 95%CI = 1.85--2.31, Table [3](#Tab3){ref-type="table"}), but there was no obvious relationship between *hMSH2* mRNA expression and PFS (*P* = 0.11, Table [3](#Tab3){ref-type="table"}). These analyses indicated that *hMSH2* mRNA expression might serve as an independent prognostic biomarker for EOC patients. Table 3Prognostic factors in epithelial ovarian cancer patients using the Cox proportional hazards modelOSPFSHR(95%CI)*P*HR(95%CI)*P*Age ≤ 50 vs \> 500.9880.63--1.560.961.140.74--1.750.54FIGO stage I--II vs III--IV0.8901.14--5.330.011.121.22--6.650.04Grade G1--2 vs G30.9920.60--1.630.970.780.49--1.230.29Tumor residual size 0 cm vs ≤ 1 cm vs \> 1 cm0.1890.09--0.360.000.240.14--0.410.00Tumor size ≤ 10 cm vs \> 10 cm1.5640.78--1.560.570.890.89--2.860.67*hMSH2* expression Low vs high1.9161.85--2.31*0.03*1.430.92--2.200.11*FIGO* International Federation of Gynecology and Obstetrics

Discussion {#Sec11}
==========

It has been suggested that DNA methylation-induced silencing of various drug response genes and pathways may facilitate the development of drug resistance in ovarian cancer. The present study revealed that (1) 5-aza-dC-induced demethylation can significantly increase the sensitivity of ovarian cancer cells to cisplatin as well as *hMSH2* expression, (2) knockdown of *hMSH2* expression could desensitize A2780 ovarian cancer cells to cisplatin, (3) the *hMSH2* upstream region was significantly hypermethylated in the EOC tissue of platinum-resistant patients, and (4) the lower expression of *hMSH2* due to hypermethylation of the upstream region was associated with the clinical outcome of patients with EOC. To the best of our knowledge, this is the first study to investigate the role of aberrant methylation of the *hMSH2* promoter region in EOC patient resistance to platinum-based chemotherapy.

Cisplatin or carboplatin in combination with paclitaxel is still the first-line chemotherapy drugs for advanced ovarian cancer. The chemotherapeutic mechanism of platinum compounds involves its covalent binding to DNA to form DNA adducts, which results in a DNA replication block and promotes cell death. hMSH2, by itself \[[@CR17]\] or as an hMSH2-hMSH6 complex \[[@CR18]\], recognizes specific DNA damage caused by cisplatin and carboplatin. In addition, hMSH2 can interact with ATR and recruit it to the sites of DNA damage, further activating a series of apoptosis proteins and resulting in apoptosis of the cells \[[@CR19]\]. Therefore, *hMSH2* is considered to play an important role in the platinum resistance of ovarian cancer.

In a preliminary genome-wide methylation screen with samples from 8 platinum-resistant and 8 platinum-sensitive EOC patients, we discovered that the methylation level of *hMSH2* upstream region (− 1193 to − 1125) was significantly higher in the resistant group. In the following in vitro studies, we discovered that global demethylation could induce higher *hMSH2* mRNA and protein level as well as a correspondingly increased cisplatin sensitivity. Knockdown of the *hMSH2* expression alone can increase cell proliferation rates and decrease apoptosis rates when challenged with the cisplatin. A recent study in a breast cancer cell line also showed that the promoter hypermethylation-mediated inactivation of the *hMSH2* gene was associated with the acquired resistance against doxorubicin, and the demethylating agent 5-aza-dC and the HDAC inhibitor Trichostatin-A significantly re-sensitized resistant cells to doxorubicin \[[@CR20]\]. Our findings are in line with this report, suggesting that the epigenetic inactivation of *hMSH2* could be one of the contributing factors for drug resistance. The therapeutic application of demethylation agents is attracting more attention to the treatment of EOC \[[@CR21]\]. Demethylation of other genes at promoter regions has been shown to restore chemotherapeutical drug responses in cancer cells \[[@CR22]--[@CR24]\]. The result from this study suggested *hMSH2* might be another target of epigenetic therapy for EOC.

The mass spectrometry results further confirmed that − 1164 upstream region of *hMSH2*, a transcription factor Mef-2, HNFα, and GR binding site (<http://jaspar.genereg.net/>), was hypermethylated in patients with platinum resistance. We also discovered that the hMSH2 mRNA and protein levels were significantly downregulated in patients with platinum resistance. Correlation analysis suggested that the methylation level of − 1164 CpG site was associated with *hMSH2* mRNA expression. These findings indicated that loss of expression due to hypermethylation of *hMSH2* upstream region might induce platinum resistance in EOC patients. In the earlier literature hypermethylation of another essential MMR gene, *hMLH1* was observed in cisplatin-resistant EOC patients \[[@CR25], [@CR26]\]. While whether loss of *hMSH2* expression caused by hypermethylation of *hMSH2* promoter contributed to platinum resistance or not in EOC was unclear previously. The results from our study provided the evidence firstly that hypermethylation of the *hMSH2* upstream region could be another mechanism for the platinum resistance in EOC patients. Interestingly, a slight increase of *hMLH1* methylation level was also observed in the platinum-resistant patients compared to the sensitive patients in our study based on the RRBS analysis. However, the differences between the two groups were not statistically significant. Indeed, there are few pieces of previous literature reporting the correlation between *hMLH1* methylation and platinum resistance based on customized or commercially available methylation array or next-generation sequence (NGS)-based platforms. What is more, none of those studies reported a clear relationship between the *hMLH1* methylation and drug resistance \[[@CR27]--[@CR29]\]. Much more need to be done in the future.

Importantly, in this study, the Kaplan-Meier analyses showed the high methylation of *hMSH2* promoter region was associated with EOC patients' worse survival. However, the obvious impact of *hMLH1* and *hMSH2* methylation on serous ovarian cancer patients' survival was not observed in TCGA dataset (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We carefully examined the dataset and discovered that there were many heterogeneity of the patients provided by TCGA dataset, particularly too many varieties on the patients' treatment plan. We believe this may be the key reason for the inconsistence between the TCGA result and our study. Further, multivariable analysis of 150 EOC patients showed that patients with lower *hMSH2* expression have a poorer prognosis than those with higher expression, which was also indicated the prognosis value of *hMSH2* methylation for EOC patients due to the negative correlation between *hMSH2* methylation and its expression.

Conclusion {#Sec12}
==========

Our study demonstrated that *hMSH2* low expression due to hypermethylation may play an important role in platinum resistance in EOC and the expression profile of *hMSH2* could be a potential biomarker for the prognosis. *hMSH2* might be a target for epigenetic therapy in platinum-resistant patients. To the best of our knowledge, this study has the largest patient number for the drug resistance research involving *hMSH2*. Though a cohort with more patients is still needed in the future, our current work still helps clarify some previous inconsistent opinions and might benefit treatment plans.

Materials and methods {#Sec13}
=====================

Cell culture {#Sec14}
------------

The human ovarian cancer cell line A2780 was purchased from iCell Bioscience Inc. (Shanghai, China) in January 2018. The cell line was authenticated by short tandem repeat (STR)-based profiling (Genetica DNA Laboratories Inc.) prior to purchase. A2780 cells were grown in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Invitrogen Gibco, NY, USA) in a humidified atmosphere with 5% CO~2~ at 37 °C.

5-aza-2′-deoxycytidine treatment {#Sec15}
--------------------------------

A2780 cells were treated with the DNA demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC, Sigma, St Louis, MO, USA) at different concentrations for 72 h, while the control cells were treated with dimethyl sulfoxide (DMSO). After the treatment, cells were collected for DNA, RNA, and protein isolation. The methylation levels of *hMSH2* were examined by MALDI-TOF mass spectrometry, and its expression was tested by RT-qPCR and western blot assay, respectively.

A2780 cells were exposed to different concentrations of cisplatin for 24 h, which had been pre-treated with 15 μM 5-aza-dC for 72 h prior to the cisplatin treatment. Afterward, cell viability and apoptosis assay were carried out in the post-treated cells.

Cell transfection and cisplatin treatment {#Sec16}
-----------------------------------------

Short hairpin RNA (shRNA) of *hMSH2* was obtained from the Gene Pharmaceutical Technology Company (Shanghai, China). The designed four target sequences in the *hMSH2* gene were 5′-GCAGCAGTCAGAGCCCCTTAAC-3′(sh-hMSH2--1038); 5′-GCAGA ATTGAGGCAGACTTTA-3′(sh-hMSH2--1233); 5'GCTTTGCTCACGTGTCAAATG-3′(sh-hMSH2--1945) and 5′-GGGCTATATCAGAATACATTG-3′(sh-hMSH2--2416). The most effective construct, recombinant plasmid inserted with *hMSH2* gene shRNA expression vector PGPU6/GFP/Neo-hMSH2-1233 was selected for the study, while a random sequence of shRNA (shNC) was used as the negative control. A2780 cells were transfected with either shRNA-hMSH2 plasmid or shNC plasmid using the Lipofectamine™2000 transfection reagent (Invitrogen, USA) according to the manufacturer's instructions. The mRNA and protein levels of hMSH2 were analyzed by RT-qPCR and western blot to confirm the transfection efficiency.

At 24 h after transfection, A2780 shRNA-hMSH2 and A2780 shNC were treated with different concentrations of cisplatin (Sigma-Aldrich, St., Louis, MO, USA) for 24 h. Thereafter, cell viability and apoptosis assays were performed to investigate the cellular response to cisplatin.

Western blot assay {#Sec17}
------------------

The collected cells were lysed in ice-cold RIPA buffer, and protein lysates were then quantified with a BCA Protein Assay Kit. Western blotting was carried out as described previously \[[@CR24]\]. The following antibodies were purchased, as indicated: a primary antibody against hMSH2 (ab92473, Abcam, Cambridge, UK), β-Actin (ab8226, Abcam, Cambridge, UK), and an anti-rabbit secondary antibody (Rockland, Gilbertsville, PA, USA). β-Actin was employed as a loading control. Immunoreactive proteins were detected by an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA), and band intensities were quantified using ImageJ.

Cell viability assay {#Sec18}
--------------------

Cell viability was assessed using a standard Cell Counting Kit-8 solution (CCK-8) (MedChemExpress USA) assay according to the manufacturer's instructions. Briefly, A2780 cells were seeded into 96-well plates. After treatment with drugs, 10 μL of CCK-8 reagent was added into every well and incubated for 3 h. The optical density was measured using a microplate reader (Thermo Fisher Scientific, Inc.) at 492 nm. Each experiment was repeated three times.

Apoptosis assay {#Sec19}
---------------

Apoptosis of A2780 cells was analyzed using an Annexin V Apoptosis Detection kit I (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, cells were seeded into 6-well plates. After treatment with drugs, the adherent cells were trypsinized without EDTA and collected by centrifugation. After washing with PBS two times, the cells were resuspended in 100 μL of 1 × binding buffer and were subsequently incubated with 5 μL of Annexin V staining solution at room temperature for 30 min in the dark. Then, 400 μL of 1 × binding buffer was added, and the fluorescence intensity was evaluated on a FACS Aria™ (BD Biosciences) flow cytometer. Each assay was performed in triplicate.

Tissue samples {#Sec20}
--------------

Tissue samples were collected from 150 patients with histologically confirmed EOC in the Hebei Medical University, Fourth Hospital, between November 2011 and June 2015. Informed consent was obtained from each participant, and this study was approved by the Institute Medical Ethics Committee of the Hebei Medical University, Fourth Hospital.

The study participants were divided into a platinum-resistant group (*n* = 60) and a platinum-sensitive group (*n* = 90) based on a platinum-free interval (PFI), which was calculated from the date of the last platinum compound treatment to the date of disease progression. Patients with a PFI of less than 6 months are considered as platinum-resistant, whereas patients with a PFI of greater than 6 months are deemed platinum-sensitive \[[@CR30]\]. All the participants were followed up for 3 years regularly. PFS and OS were used to evaluate the survival status of patients.

DNA extraction and MALDI-TOF mass spectrometry {#Sec21}
----------------------------------------------

Of the 150 EOC tissue samples, 40 yielded high-quality DNA using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. MALDI-TOF mass spectrometry (Sequenom, San Diego, California, USA), described by Breitling et al. \[[@CR31]\], was performed for *hMSH2* methylation analysis by CapitalBio Co., Ltd. (Beijing, China).

RNA extraction and real-time quantitative PCR {#Sec22}
---------------------------------------------

Total RNA was isolated from 150 EOC tissue samples using TRIZOL reagent (Generay Biotech, Co., Ltd., Shanghai, China) according to the manufacturer's protocols. The cDNA was then synthesized using a Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). The PCRs were carried out using a QuantiNova TMSYBR® Green PCR Kit (Qiagen, Hilden, Germany). Relative expression levels of *hMSH2* were calculated with the 2^--ΔCt^ method using *GAPDH* as an endogenous control, and all experiments were repeated three times.

Immunohistochemistry {#Sec23}
--------------------

Of the 150 patients, 86 paraffin-embedded EOC tissue samples obtained from the pathology department of Hebei Medical University, Fourth Hospital, were used for immunohistochemistry (IHC) staining of hMSH2. Immunohistochemical reactions were performed using anti-hMSH2 antibody (ab52266, Abcam, Cambridge, UK, dilution, 1:2000). The judgment criteria for the IHC results were that hMSH2 protein was located in the nucleus, as evaluated according to the percentage of positive staining area and the staining intensity. A sum of the 2 items ≥ 4 was defined as high expression, and a sum \< 4 was defined as low expression \[[@CR32]\]. All analyses were conducted in a double-blind manner.

Statistical analysis {#Sec24}
--------------------

All statistical analyses were performed using SPSS 21.0 statistical software package (Chicago, IL, USA). *P* value \< 0.05 was considered statistically significant. Data from cell viability assay and cell apoptosis assay were analyzed by *t* test. The comparisons of *hMSH2* methylation levels and its mRNA expression between the two groups were carried out using the Wilcoxon Rank Sum test. The *χ*^2^ test was conducted to compare hMSH2 protein expression between groups. Spearman's correlation analysis was used to evaluate the relationship between hMSH2 expression and methylation status. Kaplan-Meier analysis and Cox proportional hazard model were performed to analyze the association of *hMSH2* methylation and its expression with EOC patients' prognosis.

Supplementary information
=========================

 {#Sec25}

**Additional file 1: Figure S1.** The impact of *hMLH1* and *hMSH2* methylation on serous ovarian cancer patients' survival was presented from the TCGA dataset. (A-B) Kaplan-Meier analysis of PFS and OS according to the *hMLH1* and *hMSH2* methylation level in 496 serous ovarian cancer patients. **Additional file 2: Table S1.** Clinicopathological information for the discovery cohort patients with ovarian cancer. **Additional file 3: Table S2.** Thestatistics analysis data of 276 genes with differential methylation regions between platinum-resistant EOC tissues and platinum-sensitive EOC tissues through RRBS assay.
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